TICKERNERD
Menu
MBOTMBOTHealthcare · Medical Devices

MBOT Stock Forecast: Microbot Medical, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$1.51
+1.01% on the day

The 3 Wall Street analysts covering Microbot Medical, Inc. hold a median 12-month price target of $4 — +165.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 15 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$100.7M
Ticker Nerd rank
15 / 100
Median analyst target
$4.00
Analysts covering
3
Total return, dividends reinvested
1W
−2.9%
1M
−16.4%
YTD
−24.8%
1Y
−57.7%
From 52W high
−66.6%
From 52W low
+2.4%
$1.47
$4.50
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

MBOT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Microbot Medical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
15 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
75
Revisions
50
Growth
47
Quality
35
Volatility
32
Accruals
19
Momentum
18
Issuance
15
Value
15

Size (75): Smaller than most of the companies we track.

Value (15): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

MBOT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MBOT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00$12.00Oct 25Jan 26Apr 26Jul 26MBOTHigh $12.00Median $4.00Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says3 analysts
3 Buy0 Hold0 Sell
Low $4.00Median $4.00High $12.00

The green dot is the last close — the median target sits +165.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
14 Aug 2026B. Riley SecuritiesReiteratesBuy$5.00 → $4.00
3 June 2026LUCID CAPITAL MARKETSInitiatesBuy$4.00
3 June 2026LUCID CAPITAL MARKETSInitiatesBuy—
14 Apr 2026HC Wainwright & Co.ReiteratesBuy—
10 Feb 2026B. Riley SecuritiesInitiatesBuy—
3 Dec 2025Roth CapitalInitiatesBuy—
28 Nov 2025HC Wainwright & Co.ReiteratesBuy—
15 Oct 2025HC Wainwright & Co.ReiteratesBuy—
11 Sept 2025HC Wainwright & Co.MaintainsBuy—
10 Apr 2025HC Wainwright & Co.ReiteratesBuy—
24 Jan 2025HC Wainwright & Co.MaintainsBuy—
3 June 2024HC Wainwright & Co.ReiteratesBuy—
16 Apr 2024HC Wainwright & Co.MaintainsBuy—
18 Oct 2023HC Wainwright & Co.ReiteratesBuy—
26 June 2023HC Wainwright & Co.ReiteratesBuy—
6 June 2023HC Wainwright & Co.ReiteratesBuy—
9 May 2023HC Wainwright & Co.MaintainsBuy—
25 Nov 2020H.C. WainwrightReiteratesBuy—
25 Nov 2020HC Wainwright & Co.MaintainsBuy—
25 Nov 2020Ladenburg ThalmannDowngradeNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MBOT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

MBOT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Microbot Medical, Inc. (MBOT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−5.2×

Cheaper than 90% of US stocks

Price / sales
291.2×

Cheaper than 3% of US stocks

Price / book
1.5×

Cheaper than 57% of US stocks

EV / EBITDA
−1.9×

Cheaper than 70% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
1.9%

Higher than 5% of US stocks

Operating margin
−2567.6%

Higher than 4% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−32.9%

Higher than 26% of US stocks

Return on assets
−21.7%

Higher than 18% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

MBOT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
MBOTMicrobot Medical, Inc.$100.7M
15
LNSRLENSAR, Inc.$103.6M
60
HYPRHyperfine, Inc.$95.7M
56
ECORelectroCore, Inc.$94.8M
54
LUNGPulmonx Corp.$93.2M
74
SERASera Prognostics, Inc.$83.8M
40
RPIDRapid Micro Biosystems, Inc.$83.7M
32

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Microbot Medical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MBOT news & analysis

Microbot Medical Inc. (MBOT) Reports Q2 Loss, Lags Revenue Estimates

Zacks Investment Research · 11 Aug 2026neutral

Microbot Medical Inc. reported a second-quarter loss of $0.08 per share, matching the Zacks Consensus Estimate and improving from a loss of $0.10 per share a year earlier. Revenue lagged estimates for the quarter.

Why it matters — MBOT watchers would care because the quarterly earnings result was in line with expectations and showed improvement over the prior-year loss, though revenue fell short of estimates.

FAQ

Frequently asked questions about MBOT stock

What is the MBOT stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Microbot Medical, Inc. have a median 12-month price target of $4, with estimates ranging from $4 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MBOT stock a buy right now?

Of the 3 analysts covering Microbot Medical, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Microbot Medical, Inc. 15 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MBOT?

As at 22 Aug 2026, Microbot Medical, Inc. ranks 15 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (75 of 100).

Will MBOT stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +165.8% from the last close, and Ticker Nerd's factor model ranks Microbot Medical, Inc. 15 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MBOT stock forecast for 2030?

No analyst covering Microbot Medical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MBOT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $12 over the next 12 months.

How has MBOT stock performed over the past year?

Microbot Medical, Inc. returned -57.7% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Microbot Medical, Inc. do?

Microbot Medical Inc. is a cutting-edge medical device company focused on enhancing healthcare through innovative technologies.

What is the latest news on MBOT?

The most recent item we track (Zacks Investment Research, 11 Aug 2026): "Microbot Medical Inc. (MBOT) Reports Q2 Loss, Lags Revenue Estimates". Microbot Medical Inc. reported a second-quarter loss of $0.08 per share, matching the Zacks Consensus Estimate and improving from a loss of $0.10 per share a year earlier. Revenue lagged estimates for the quarter.

Company

About Microbot Medical, Inc.

Microbot Medical Inc. is a cutting-edge medical device company focused on enhancing healthcare through innovative technologies. The company's primary function is to develop micro-robotic medical solutions, with an emphasis on improving minimally invasive surgeries and medical procedures. This focus addresses the growing demand for precision, efficacy, and less invasive treatment options within the healthcare sector. Notably, Microbot Medical Inc. is pioneering advancements in the field of robotic technology to facilitate endoluminal procedures, which involve navigation through natural body lumens such as blood vessels or the gastrointestinal tract. With its headquarters in Massachusetts, USA, the company plays a significant role in the medical device market, contributing to the ongoing evolution of surgical practices and patient care. As healthcare providers increasingly prioritize technological advancements to reduce recovery times and enhance procedural accuracy, Microbot Medical Inc.'s innovations become crucial to achieving these goals. The company's commitment to micro-robotics positions it as a transformative entity within the healthcare technology landscape.

CEO Mr. Harel Gadot · 43 employees · United States · https://microbotmedical.com